COMMUNIQUÉS West-GlobeNewswire

-
Apixio’s AI-Based Technology Delivers More Accurate Risk Adjustment to Meet Industry Demand for Compliant Solutions
19/12/2017 -
INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric Patients
19/12/2017 -
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
19/12/2017 -
Xbrane Biopharma signs agreement with BL&H for sales and marketing of Spherotide in South Korea
19/12/2017 -
Cancer Genetics Receives New York State Approval for FDA-Approved Oncomine Dx Target Test by Thermo Fisher Scientific
19/12/2017 -
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
19/12/2017 -
REPEAT – Cannabis Wheaton Income Corp. Announces Exclusive Data Licensing Agreement With Prominent Cannabis Testing, Analysis and Rating Company
19/12/2017 -
Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5
19/12/2017 -
Myriad Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
19/12/2017 -
Faron Pharmaceuticals Oy: Study update: Traumakine® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC
19/12/2017 -
PTS Diagnostics Announces New Portable Data Capture System for Screening Professionals
19/12/2017 -
REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II
19/12/2017 -
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
19/12/2017 -
Axsome Therapeutics to Present at Biotech Showcase 2018
19/12/2017 -
Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo
19/12/2017 -
COPE Health Solutions expands COPE Health Scholars programs to Hawaii with Adventist Health Castle
19/12/2017 -
ImmuCell Corporation Announces Pricing of $3 Million Public Offering of Common Shares
19/12/2017 -
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018
19/12/2017 -
Amphastar Announces Approval for Sodium Nitroprusside Injection, USP
19/12/2017
Pages